NCT01011777 (MDC) is a Phase 1 clinical trial of MDC in Bladder Exstrophy, sponsored by Johns Hopkins University.

Who is sponsoring NCT01011777?

NCT01011777 is sponsored by Johns Hopkins University.

What drugs are being tested in NCT01011777?

Interventions in NCT01011777: MDC.

What condition does NCT01011777 study?

NCT01011777 studies Bladder Exstrophy, Urinary Incontinence.

Is NCT01011777 still recruiting?

NCT01011777 is currently terminated. Last updated 28 January 2020.

Last reviewed 2020-01-28 · How we verify

NCT01011777: MDC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Muscle Derived Cell Therapy for Bladder Exstrophy Epispadias Induced Incontinence

Terminated Phase 1 Last updated 28 January 2020

What this trial tests

Phase 1 trial testing MDC in Bladder Exstrophy in 2 participants. Terminated before completion.

Timeline

1 February 2017

Primary endpoint
23 January 2020

23 January 2020

Quick facts

Lead sponsor	Johns Hopkins University
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	1 February 2017
Primary completion	23 January 2020
Estimated completion	23 January 2020
Sites	1 location across United States

Drugs / interventions tested

MDC — full drug profile →

Conditions studied

Bladder Exstrophy — all drugs for Bladder Exstrophy →
Urinary Incontinence — all drugs for Urinary Incontinence →

Sponsor

Johns Hopkins University

Who can join

2 and older, any sex, with Bladder Exstrophy or Urinary Incontinence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to study safety, tolerability and efficacy of muscle derived cell (MDC) therapy in children with bladder exstrophy epispadias induced urinary incontinence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Johns Hopkins University trials

Trials by the same sponsor.

NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety · NA · not yet recruiting
NCT07532252 — Daridorexant for Alcohol Use Disorder · Phase 2 · not yet recruiting
NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea · Phase 1, PHASE2 · not yet recruiting
NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use · NA · not yet recruiting
NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01011777 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
Last refreshed: 28 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01011777.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing